The abstract is read at the publisher; the summary is JClub's.
Disrupting the PKD1 3'UTR miR-17 site increases polycystin-1 dosage and attenuates cystic disease in experimental models of autosomal dominant polycystic kidney disease.
- Why it matters: ADPKD is linked to insufficient functional polycystin-1 from heterozygous PKD1 mutations, but how residual alleles are constrained at the RNA level remains incompletely defined.
- What they did: The review synthesizes genetic, molecular, and therapeutic evidence for a dosage-threshold model, emphasizing post-transcriptional control by PKD1 5' and 3' untranslated regions and miR-17 targeting.
- The result: Genetic disruption or pharmacologic inhibition of miR-17 raises polycystin dosage and reduces cystic disease in experimental models, and Farabursen shows early clinical pharmacodynamic signals consistent with polycystin-1 and polycystin-2 derepression, now in Phase 3 development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.